Pegylated interferon plus ribavirin combination therapy for chronic hepatitis C in patients with congenital coagulation disorders

Acta Haematologica

Volumn 120, Issue 2, 2008, Pages 63-69

  Katsarou, O ^a   Theodosiades, G ^b   Ioannidou, P ^a   Nomikou, E ^b   Tsevrenis, B ^b   Kouraba, A ^a   Deutch, M ^b   Terpos, E ^a   Dourakis, S ^b   Karafoulidou, A ^a  

^a LAIKO GENERAL HOSPITAL   (Greece)

^b HIPPOKRATION HOSPITAL   (Greece)

Author keywords

Chronic hepatitis C treatment; Hemophilia; Hepatitis C; Human immunodeficiency virus

Indexed keywords

DIDANOSINE; EFAVIRENZ; LAMIVUDINE; NEVIRAPINE; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PROTEINASE INHIBITOR; RIBAVIRIN; STAVUDINE; ZIDOVUDINE;

ADULT; AGED; ANEMIA; ARTICLE; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DEPRESSION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FLU LIKE SYNDROME; GENOTYPE; HEMOPHILIA; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTHYROIDISM; INJECTION SITE REACTION; MALE; NEUTROPENIA; PRIORITY JOURNAL; SIDE EFFECT; THYROID DISEASE; TREATMENT RESPONSE; WEIGHT REDUCTION;

ADOLESCENT; ADULT; AGED; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BLOOD COAGULATION DISORDERS, INHERITED; DRUG THERAPY, COMBINATION; DRUG TOXICITY; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; INTERFERON ALFA-2A; MIDDLE AGED; POLYETHYLENE GLYCOLS; RIBAVIRIN; RNA, VIRAL; TREATMENT OUTCOME; YOUNG ADULT;

EID: 52649104469     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000158630     Document Type: Article

References (31)

1. Triemstra M, Rosendaal FR, Smit C, Van der Ploeg HM, Briet E: Mortality in patients with hemophilia. Ann Intern Med 1995;123:823-827.
2. Darby SC, Ewart DW, Giangrande PLF, Spooner RJD, Rizza CR, Dusheiko GM, Lee CA, Ludlam CA, Preston FE: Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C. Lancet 1997;350:1425-1431.
3. Plug I, Van Der Bom JG, Peters M, Mauser-Bunxchoten EP, De Goede-Bolder A, Heijnen L, Smit C, Willemse J, Rosendaal FR: Mortality and causes of death in patients with hemophilia 1992-2001: a prospective cohort study. J Thromb Haemost 2006;4:510-516.
4. Hatzakis A, Polychronaki H, Miriagou V, Yannitsiotis A, Chrispeels J, Troonen H, Karafoulidou A, Gialeraki A, Katsouyanni K, Mandalaki T: Antibody responses to hepatitis C virus by second-generation immunoassays in a cohort of patients with bleeding disorders. Vox Sang 1992;63:204-209.
5. Touloumi G, Karafoulidou A, Gialeraki A, Katsarou O, Milona I, Kapsimali V, Mandalaki T, Hatzakis A: Determinants of progression of HIV infection in a Greek hemophilia cohort followed for up to 16 years after seroconversion. J Acquir Immune Defic Syndr Hum Retrovirol 1998;19:89-97.
6. Eyster ME, Diamondstone LS, Lien JM, Ehmann WC, Quan S, Goedert JJ: Natural history of hepatitis C virus infection in multitransfused hemophiliacs effect of coinfection with human immunodeficiency virus. Multicenter Hemophilia Cohort Study. J Acquir Immune Defic Syndr Hum Retrovirol 1993;6:602-610.
7. Telfer P, Sabin C, Devereux H, Scott F, Dusheiko G, Lee C: The progression of HCV-associated liver disease in a cohort of hemophilic patients. Br J Haematol 1994;87:555-561.
8. Makris M, Preston FE, Rosendaal FR, Underwood JC, Rice KM, Triger DR: The natural history of chronic hepatitis C in haemophiliacs. Br J Haematol 1996;94:746-752.
9. Posthouwer D, Makris M, Yee TT, Fischer K, van Veen JJ, Griffioen A, van Erpecum KJ, Mauser-Bunschoten EP: Progression to end-stage liver disease in patients with inherited bleeding disorders and hepatitis C: an international, multicenter cohort study. Blood 2007;109:3667-3671.
10. Mocroft A, Vellas S, Bentied TL, Chiesi A, Miller V, Gargalianos P, d'Arminio Monforte A, Yust I, Bruun JN, Phillips AN, Lundgren JD: Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet 1998;352:1725-1730.
11. Katsarou O, Touloumi G, Antoniou A, Kouramba A, Hatzakis A, Karafoulidou A: Progression of HIV infection in the post-HAART era among a cohort of HIV+ Greek haemophilia patients Haemophilia 2005;11:360-365.
12. Posthouwer D, Mauser-Bunschoten EP, Fischer K, Makris M: Treatment of chronic hepatitis C in patients with haemophilia: a review of the literature. Haemophilia 2006;12:473-478.
13. Sauleda S, Juarez A, Esteban J, Altisent C, Ruiz I, Puig L, Esteban R, Guardia J: Interferon and ribavirin combination therapy for chronic hepatitis C in human immunodeficiency virus-infected patients with congenital coagulation disorders. Hepatology 2001;34:1035-1040.
14. Fried MW, Shiffman ML, Reddy RK, Smith C, Marinos G, Goncales FL Jr, Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J: Peg interferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-982.
15. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK: Peg-interferon alfa-2b in combination with ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: results of a randomized trial. Lancet 2001;358:958-965.
16. Torriani FJ, Rodriquez-Torres M, Rockstroh JK, Lissen E, Gonzalez-Garcia J, Lazzarin A, Carosi G, Sasadeusz J, Katlama C, Montaner J, Sette H Jr, Passe S, De Pamphilis J, Duff F, Schrenk UM, Dieterich DT;APRICOT Study Group: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIVinfected patients. N Engl J Med 2004;351:438-450.
17. Carrat F, Bani-Sadr F, Pol S, Rosenthal E, Lunel-Fabiani F, Benzekri A, Morand P, Goujard C, Pialoux G, Piroth L, Salmon-Ceron D, Degott C, Cacoub P, Perronne C; RIBAVIC Study Team: Pegylated interferon alfa-2b vs. standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA 2004;292:2839-2848.
18. Laguno M, Murillas J, Blanco JL, Martinez E, Miquel R, Sanchez-Tapias JM, Bargallo X, Garcia-Criado A, de Lazzari E, Larrousse M, Leon A, Lonca M, Milinkovic A, Gatell JM, Mallolas J: Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV coinfected patients. AIDS 2004;18:F27-F36.
19. Mancuso ME, Rumi MG, Santagostino E, Linari S, Coppola A, Mannucci PM, Colombo M; Hepatitis Study Group of the Association of Italian Hemophilia Centers: High efficacy of combined therapy with pegylated interferon plus ribavirin in patients with hemophilia and chronic hepatitis C. Haematologica 2006;91:1367-1371.
20. Strader DB, Wright T, Thomas DL, Seeff LB: Diagnosis, management and treatment of hepatitis C. Hepatology 2004;39:1147-1171.
21. Posthouwer D, Yee TT, Makris M, Fischer K, Griffioen A, Van Veen JJ, Mauser-Bunschoten EP: Antiviral therapy for chronic hepatitis C in patients with inherited bleeding disorders: an international, multicenter cohort study. J Thromb Haemost 2007;5:1624-1629.
22. Maor Y, Schapiro JM, Bashari D, Lurie Y, Safadi R, Segol O, Paritsky M, Rachlis Z, Avidan B, Bar-Meir S, Martinowitz U: Treatment of hepatitis C in patients with haemophilia - the Israeli National Hemophilia Center experience. Haemophilia 2008;14:336-342. Epub 2008.
23. Perronne C, Carrat F, Banisadr F, Morand P, Lunel F, Rosenthal E, Pol S: ANRS HC02-RIBAVIC: a randomized controlled trial of pegylated interferon alfa-2b plus ribavirin versus interferon alfa-2b plus ribavirin as primary treatment of chronic hepatitis C in HIV-coinfected patients. Hepatology 2002;36:283A.
24. Garcia-Benayas T, Blanco F, Soriano V: Weight loss in HIV-infected patients. N Engl J Med 2002;347:1287-1288.
25. Mauss S, Valenti W, DePamphilis J, Duff F, Cupelli L, Passe S, Solsky J, Torriani FJ, Dieterich D, Larrey D: Risk factors for hepatic decompensation in patients with HIV/HCV coinfection and liver cirrhosis during interferon-based therapy. AIDS 2004;18:F21-F25.
26. Soriano V, Puoti M, Sulkowski M, Mauss S, Cacoub P, Cargnel A, Dieterich D, Hatzakis A, Rockstroh J: Care of patients with hepatitis C and HIV co-infection. AIDS 2004;18:1-12.
27. Delladetsima J, Katsarou O, Touloumi G, Vgenopoulou S, Hatzakis A, Karafoulidou A: Significance of immune status, genotype and viral load in the severity of chronic hepatitis C in HIV infected haemophilia patients. Haemophilia 2002;8:668-673.
28. Rockstroh JK, Spengler U Sudhop T, Ewig S, Theisen A, Hammerstein U, Bierhoff E, Fischer HP, Oldenburg J, Brackmann HH, Sauerbruch T: Immunosuppression may lead to progression of hepatitis C virus-associated liver disease in hemophiliacs coinfected with HIV. Am J Gastrenterology 1996;91:2563-2568.
29. Chung R, Andersen J, Volberding P, Robbins KG, Liu T, Sherman EK, Peters MG, Koziel MJ, Bhan AK, Alston B, Colquhoun D, Nevin T, Harb G, van der Horst C: Peginteferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004;351:451-459.
30. McGovern BH, Ditelberg JS, Taylor LE, Gandhi RT, Christopoulos KA, Chapman S, Schwartzapfel B, Rindler E, Fiorino AM, Zaman MT, Sax PE, Graeme-Cook F, Hibberd PL: Hepatic steatosis is associated with fibrosis, nucleoside analogue use, and hepatitis C virus genotype 3 infection in HIV-seropositive patients. Clin Infect Dis 2006;43:365-372.
31. Reddy KR, Govindarajan S, Marcellin P, Bernstein D, Dienstag JL, Bodenheimer H Jr, Rakela J, Messinger D, Schmidt G, Ackrill A, Hadziyannis SJ: Hepatic steatosis in chronic hepatitis C: baseline host and viral characteristics and influence on response to therapy with peginterferon alpha-2a plus ribavirin. J Viral Hepat 2008;15:129-136.